Hereditary breast and ovarian cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. The Contribution of Genetic Modifiers to Ovarian Cancer Risk inCancers · 2026
   Review
2. Insights into genetic modifiers of breast cancer risk in carriers of BRCA1 and BRCA2 pathogenic variants.Hereditary cancer in clinical practice · 2025
   Review
3. Understanding genetic variations associated with familial breast cancer.World journal of surgical oncology · 2024
   Review
4. Underpinnings of the Halachic Approach to BRCA Screening and Intervention: Facilitating Provider Counseling for Observant Jewish Populations.Rambam Maimonides medical journal · 2024
   Review
5. Synchronous and Metachronous Breast and Ovarian Cancers: Experience from a Single Tertiary Care Cancer Centre in India.Indian journal of surgical oncology · 2023
   Article
6. Genetic alterations detected by comparative genomic hybridization in BRCAX breast and ovarian cancers of Brazilian population.Oncotarget · 2018
   Article
7. The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review.Clinical & experimental metastasis · 2017
   Review
8. Genetic and epigenetic characterization of the BRCA1 gene in Brazilian women at-risk for hereditary breast cancer.Oncotarget · 2017
   Article
9. μ-Opioid receptor gene (OPRM1) polymorphism in patients with breast cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
   Article
10. Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers.PloS one · 2015
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

10 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.